About Us
We are a privately held biotechnology company pioneering the development and commercialization of promising first-in-class repurposed artemisinin-based therapeutics for cancer, inflammation and infectious diseases.
|
Mission
Our mission is to establish an integrated specialty pharmaceutical company for the design, development and advancement of novel classes of therapeutics that will offer more highly selective, effective and safer treatment options for people and companion animals afflicted with cancer, other serious proliferative and inflammatory disorders, and infectious diseases.
|
History
The use of novel artemisinin compounds to treat cancer was first studied in the early 1990's. Around the same time, a series of new artemisinin compounds called trioxane dimers were being synthesized and developed. A trioxane dimer consists of two artemisinin molecules permanently attached together by a linker. Originally developed for malaria, artemisinin dimers have been found to possess both potent anti-malarial activity and anti-cancer activities, while retaining the excellent safety profile of the parent molecule.
|
1993. Artemisinin is tested against leukemia and breast cancer cells. Co-administration of artemisinin and transferrin, an iron-carrying protein, produces rapid death in these cancer cells while having virtually no effect on corresponding normal cells.
2004. A conjugated compound is developed in which artemisinin is permanently attached to transferrin, delivering a targeted therapy in one package via the cell membrane transferrin receptor, and further enhancing the selectivity and toxicity of artemisinin towards cancer cells.
2005. Even more selective and effective therapies for cancer are developed, including artemisinin attached to iron-binding molecules (chelators) that starve cancer cells and activate artemisinin, and artemisinin attached to transferrin receptor-binding peptides.
2006. Artemisia BioMedical is founded to continue development and commercialization of these and other promising new therapeutics.
2009~ Novel artemisinin dimers and conjugated compounds are developed with enhanced selectivity and powerful anti-cancer and anti-malarial effects.
|
Legal Disclaimer. All content of this website is the property of Artemisia BioMedical, and is protected by international copyright laws. Download of content is permitted only for non-commercial purposes, and no modification or reproduction of the content is allowed. Any communication sent to this website, or to Artemisia BioMedical, by email are on a non-confidential basis. Artemisia BioMedical is under no obligation to refrain from reproducing, publishing or using such email in any manner unless otherwise agreed in writing. Any links to other websites are provided as convenience, and Artemisia BioMedical takes no responsibility for the content of such other websites and shall not be liable for any damages or injury arising from that content.
|
Medical Information. This website may contain information related to certain medical conditions and treatments therefor. This information is not meant to be, nor should it be considered as, medical advice. Should you have, or suspect you have, a medical condition, you should promptly contact your physician or healthcare provider.
|
Forward-Looking Statements. Artemisia BioMedical, Inc is a privately held corporation. This website, and any documents issued by Artemisia BioMedical and available through this website, may contain statements that constitute forward-looking statements within the context and meaning of the U.S. Private Securities Litigation Reform Act of 1995. Those statements can be identified by the use of words such as "believe", "expect", "plan", "may", "will", "should", "anticipate" or similar statements or the negative of these words. These forward-looking statements are based on the Company's current expectations. Known and unknown internal and external risks and uncertainties may cause the actual results to be materially different from those expressed in or implied by the forward-looking statements. Artemisia BioMedical undertakes no obligation to update forward-looking statements to reflect events or circumstances that occur after the date the statements were made.
|
|